Clinical trials: Ticagrelor
Critical Illness
High "on Treatment" Platelet Reactivity in the Intensive Care Unit
High "on treatment" platelet reactivity is defined as a poor pharmacodynamic response to the administration of acetylsalicylic acid or clopidogrel.
- Trial name
- NCT02285751
- Testing
- acetylsalicylic acid, clopidogrel, prasugrel
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Peripheral Arterial Disease
Ticagrelor and Peripheral Arterial Disease
This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.
- Trial name
- NCT02407314
- Testing
- Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Arkansas Heart Hospital
Coronary Artery Disease, Endothelial Function
Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease
Ticagrelor administration, whose molecule resembles to adenosine, led to reduction in overall mortality and thrombotic cardiovascular (CV) events when directly compared to clopidogrel in the PLATO trial, implicating possible…
- Trial name
- NCT01957540
- Testing
- Ticagrelor, Prasugrel
- Where
- Greece
- Volunteers
- 22 people
- Sponsor
- University of Patras
Myocardial Infarction, No-Reflow Phenomenon
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
The patients with acute myocardial infarction (AMI) present high mortality and morbidity rate,even treated with stenting in the blocked heart vessels. The appearance of no-reflow is common after re-opening of the blocked vessel.
- Trial name
- NCT02233790
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
Ischemic Stroke
Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever minor stroke or TIA compared to 200mg cilostazol were assessed through NIHSS…
- Trial name
- NCT06591390
- Testing
- Ticagrelor 90 MG, Cilostazol 100 MG
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Coronary Artery Disease
The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)
With potent analgesic properties, perceived hemodynamic benefits and limited alternatives, opiates are the analgesic mainstay for acute coronary syndrome (ACS) patients reporting peri-procedural pain or nitrate-resistant chest…
- Trial name
- PACIFY (NCT02683707)
- Testing
- Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- Johns Hopkins University
Coronary Artery Disease
Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
Recently, two P2Y12 receptor inhibitors have been approved for clinical use: prasugrel and ticagrelor. Both prasugrel and ticagrelor have shown to be associated with more potent antiplatelet effects compared with clopidogrel and…
- Trial name
- NCT01852175
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Florida
Acute Coronary Syndrome
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12…
- Trial name
- GEMINI ACS 1 (NCT02293395)
- Testing
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel
- Where
- 259 sites in United States, Argentina and 18 more
- Volunteers
- 3,037 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Kidney Diseases, Heart Attack
Chronic Kidney Disease (CKD) Platelet Study
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys.
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Trial name
- NCT03649711
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Myocardial Infarction
Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)
In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogrel and ticagrelor 180 mg loading dose will…
- Trial name
- NCT03613857
- Testing
- Clopidogrel, Ticagrelor 90mg
- Where
- Egypt
- Volunteers
- 1,022 people
- Sponsor
- Cairo University
Patients Who Are Scheduled to Undergo a PCI (Percutaneous Coronary Intervention) for CTO (Chronic Total Occlusion)
TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization
The study is a single-centre, randomized, active controlled, open label clinical trial. The primary hypothesis is that ticagrelor will show superiority over clopidogrel immediately after CTO-PCI (chronic total occlusion …
- Trial name
- TIGER-BVS (NCT02211066)
- Testing
- Clopidogrel, Ticagrelor
- Where
- 2 sites in Spain
- Volunteers
- 59 people
- Sponsor
- Hospital Clinic of Barcelona
Ischemia
The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males
To test the effect of atorvastatin or placebo in combination with ticagrelor on ACh-induced vasodilatation of the forearm resistance vasculature as assessed by forearm blood flow (FBF) measurement before and 10 min after a 20 min…
- Trial name
- NCT02910778
- Testing
- Atorvastatin, Ticagrelor
- Where
- Austria
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Antiplatelet Therapy, Coronary Artery Disease
LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
The hypothesis in this study was that ticagrelor switched to 60 mg after 1 month of standard dose, with antiplatelet activity that is not inferior to the standard dose and better than 75 mg clopidogrel for patients with ACS after…
- Conditions
- Antiplatelet Therapy, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- LOTIC (NCT04060914)
- Testing
- Ticagrelor 90mg, Ticagrelor 90mg/60mg, Clopidogrel 75mg
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Beijing Anzhen Hospital
Diabetes Mellitus, Microvascular Coronary Artery Disease
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.
This study is designed to test the hypothesis that ticagrelor is superior to clopidogrel, in improving coronary microvascular function, as measured by coronary flow reserve (CFR) in patients with T2DM at high risk of…
- Trial name
- AUGEAS (NCT04069234)
- Testing
- Ticagrelor, Clopidogrel
- Sponsor
- Region Skane
Acute Coronary Syndrome
Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting
To investigate pleiotropic effects of ticagrelor in addition to its antiplatelet effects in type 2 diabetic patients with non-ST elevation acute coronary syndrome by measuring inflammatory markers, circulating number of…
- Trial name
- NCT02487732
- Testing
- Ticagrelor, Prasugrel
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Korea University Anam Hospital
STEMI
Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI
Platelets and thrombus formation play a key role in the pathogenesis of acute coronary artery occlusion and subsequent myocardial infarction.
- Trial name
- NCT02943369
- Testing
- Ticagrelor 180 mg loading dose, Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min
- Where
- Greece
- Volunteers
- 30 people
- Sponsor
- Attikon Hospital
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 with and…
- Trial name
- NCT03492385
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Insomnia
A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
Primary Objective : To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects; Secondary Objective: To evaluate the safety of ticagrelor tablets in combination with…
- Trial name
- NCT06671470
- Testing
- YZJ-1139 tablets, Ticagrelor Tablets
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Coronary Heart Disease
Pharmacodynamic and Short-term Effects of Half-dose Ticagrelor With or Without Aspirin vs DAPT From Day of PCI in CCS
Six months of aspirin plus clopidogrel remains the recommended antiplatelet regimen after percutaneous coronary intervention (PCI) for chronic coronary syndrome (CCS), with the more potent P2Y₁₂ inhibitors reserved for the acute…
- Trial name
- NCT07622056
- Testing
- Aspirin 100 mg + clopidogrel (300 mg load → 75 mg daily) ×6 months, then aspirin monotherapy, Aspirin 100 mg + ticagrelor (90 mg load → 45 mg twice daily) ×6 months, then aspirin monotherapy, Ticagrelor (90 mg load → 45 mg twice daily) monotherapy; aspirin stopped at day 2 after randomisation; continued indefinitely
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- Kaohsiung Veterans General Hospital.
ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST…
- Trial name
- TASTER (NCT03822377)
- Testing
- Ticagrelor orodispersible tablets, Ticagrelor standard tablets
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero Universitaria di Sassari